Na-tartrate in the treatment of chronic nonbacterial prostatitis.
In an open investigation 20 patients with a history of chronic abacterial prostatitis (24 month duration) and of multiple therapies were treated by 0.07-0.15/kg Na-tartrate. Na-tartrate, a known inhibitor of the prostatic fraction of acid phosphatase in laboratory studies, was given orally for 12 weeks after dissolution in fluids and well tolerated. 13 patients completed the study and 3 spermiograms at 6 weeks interval were performed. 11/13 patients demonstrated increased sperm count (44.5 +/- 26.4 leads to 55.06 +/- 34.7) elevated seminal prostatic phosphatase (727 +/- 114.7 leads to 810.8 +/- 55.7) and improved seminal testosterone (2.86 +/- 1.6 leads to 4 +/- 1.4) while seminal y-GT was not significantly changed. Polyamine excretion showed a distinct elevation for putrescine 17.7 +/- 5.3 leads to 28.5 +/- 6.8. Clinically the 11 from 13 patients presented with marked improvement in a 4 months follow-up.
D000135:Acid Phosphatase / Q000378:metabolism; D000328:Adult; D006801:Humans; D006863:Hydrogen-Ion Concentration; D007986:Luteinizing Hormone / Q000378:metabolism; D008297:Male; D008875:Middle Aged; D011073:Polyamines / Q000652:urine; D011472:Prostatitis / Q000188:drug therapy* / Q000378:metabolism; D012661:Semen / Q000378:metabolism; D013076:Sperm Count; D013644:Tartrates / Q000627:therapeutic use*; D013739:Testosterone / Q000378:metabolism
D011073:Polyamines; D013644:Tartrates; D013739:Testosterone; D007986:Luteinizing Hormone; D000135:Acid Phosphatase; C029768:tartaric acid